Core Insights - Korro Bio, Inc. is recognized as one of the best biotech stocks under $20, with significant potential for investment [1] Company Overview - Korro Bio, Inc. is a biopharmaceutical company focused on developing precision genetic medicines through RNA editing to address both rare and prevalent diseases [4] - The company utilizes its proprietary OPERA platform to advance RNA-editing therapies, which include both clinical and preclinical programs [4] Analyst Upgrades - H.C. Wainwright upgraded Korro Bio, Inc. from Neutral to Buy with a price target of $20, emphasizing the independent value of KRRO-121 as a second risk-mitigated asset [2] - Chardan Capital also upgraded Korro Bio, Inc. from Neutral to Buy with a price target of $15, citing strong preclinical data for KRRO-121 and indicating that the company has "turned the page" [3]